SecBot SecBot

IVA

Inventiva S.A.
Nasdaq· Pharmaceutical Preparations· Inc. I0· CIK 0001756594 Biotech & Drug Discovery
$3.66 −0.05 (−1.35%)
Oct 26 4:00 PM ET · prev $3.71
Market cap
$850.6M
Small cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$14.00
+283% · range $10.00–26.00
1 year
−47.0%
from $6.90 · Oct 27
30 days
+3.7%
from $3.53
52-week range
$2.87–7.15
−49% from high · low Oct 13
Avg volume 20D
3.45M
shares / day
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3
Strongest MIXED Inventiva reported H1 2026 financial results showing a net loss of €69.5 million, improved from €175.9…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q2 2026: 10 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.230 → −$0.159 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    6% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCDOUBLED1,784,566$6.7M
AMERIPRISE FINANCIAL INCDOUBLED1,697,148$6.4M
Point72 Asset Management, L.P.ADD1,683,012$6.4M
Polar Capital Holdings PlcTRIM1,074,214$4.1M
MARSHALL WACE, LLPADD965,907$3.7M
MORGAN STANLEYADD901,640$3.4M
JANE STREET GROUP, LLCDOUBLED901,369$3.4M
Quadrature Capital LtdDOUBLED207,182$783.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy7Buy7Hold1Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +283%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 2, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Sep 29, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Sep 15, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Jul 17, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight

Earnings setup

Estimates
−$0.16
EPS estimate, this quarter
+31%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.16-$0.16–-$0.16+16.3%$0.00
Next Q-$0.16-$0.16–-$0.16+11.7%$0.00
Current FY-$0.68-$0.85–-$0.52+15.8%$5.1M
Next FY-$0.74-$1.07–-$0.43+12.2%$2.2M
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 30, 2026
Short interest
Short Interest: IVA up 72% to 8.3M shares
Settlement 2026-09-30 | Days to cover: 3.27 | ≈3.53% of shares outstanding (est.)
Sep 15, 2026
Short interest
Short Interest: IVA up 32% to 4.9M shares
Settlement 2026-09-15 | Days to cover: 3.55 | ≈2.05% of shares outstanding (est.)
Sep 9, 2026
Clinical Trial
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
Phase 2 · COMPLETED
Aug 31, 2026
Short interest
Short Interest: IVA up 43% to 3.7M shares
Settlement 2026-08-31 | Days to cover: 5.32 | ≈1.56% of shares outstanding (est.)
Apr 7, 2026
Short interest
FTD: IVA — 136,000 shares ($0.8M) failed to deliver
Settlement: 20260407, Price: $5.67, FTD Value: $771,120, INVENTIVA SA ADR (FRA)

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 6, 2026 SEC
Inventiva announced the presentation of three scientific abstracts at the upcoming AASLD The Liver Meeting 2026…
6-K — Impact 3/10
Sep 30, 2026 Short interest report
Short Interest: IVA up 72% to 8.3M shares
Settlement 2026-09-30 | Days to cover: 3.27 | ≈3.53% of shares outstanding (est.)
Sep 28, 2026 SEC
Inventiva reported H1 2026 financial results showing a net loss of €69.5 million, improved from €175.9 million in H1…
6-K — Impact 6/10
Sep 3, 2026 SEC
Inventiva announced the last patient completed the final 72-week visit in the pivotal NATiV3 Phase 3 trial of…
6-K — Impact 7/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
1,784,566 shares ($6.7M)
Jun 30, 2026 Inst.
AMERIPRISE FINANCIAL INC — DOUBLED
1,697,148 shares ($6.4M)
Reddit

Fresh Reddit data

The last 24 hours of Reddit activity are for subscribers.

Subscribe for Full Access
Recent comments
r/pennystocks1d ago
Fresh comment, for subscribers
All social signals and their track records

SecBot reports

6 filings · 1 bullish · 0 bearish · 2 mixed · 3 neutral
All IVA filing & press-release reports (6)